LYL273 for Patients With Relapsed or Refractory mCRC | MicrobiomeTrials← Back to trialsNCT05319314
LYL273 for Patients With Relapsed or Refractory mCRC
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2022-08-01Est. Completion: 2028-06
Enrollment target: 155 participants Locations- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- University of California San Francisco Medical Center, San Francisco, California, United States
- University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- SCRI Oncology Partners and Tristar Centennial Hospital, Nashville, Tennessee, United States
Other microbiome trials you might be interested in
Colorectal NeoplasmsNeoplasmsIntrahepatic CholangiocarcinomaAdrenocortical CarcinomaMetastasis, Neoplasm
Background:
Cancers that begin in the colon, adrenal glands, or bile ducts may spread to the liver. These liver tumors …
Bethesda, United StatesEst. completion Dec 31, 2029
Breast CancerDiabetesColon CancerCardiovascular Disease
This study will examine what methods work best for encouraging Mexican-American family members to talk about their risk …
Colorectal NeoplasmsGastric NeoplasmsCholangiocarcinomaBile Duct CancerPancreas Cancer
Background:
\- Recent advances in cancer research have led to new therapies to treat the disease. It is important to co…
Bethesda, United StatesEst. completion Jun 30, 2035